Interim thymus and activation regulated chemokine versus interim F-18-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
60 Downloads (Pure)

Abstract

Serum thymus and activation regulated chemokine (TARC) levels reflect classical Hodgkin lymphoma (cHL) disease activity and correspond with treatment response. We compared mid-treatment interim TARC (iTARC) with interim 18 F-fluorodeoxyglucose positron-emission tomography (iPET) imaging to predict modified progression-free survival (mPFS) in a group of 95 patients with cHL. High iTARC levels were found in nine and positive iPET in 17 patients. The positive predictive value (PPV) of iTARC for a 5-year mPFS event was 88% compared to 47% for iPET. The negative predictive value was comparable at 86% for iTARC and 85% for iPET. Serum iTARC levels more accurately reflect treatment response with a higher PPV compared to iPET.

Original languageEnglish
Pages (from-to)40-44
Number of pages5
JournalBritish Journal of Haematology
Volume190
Issue number1
DOIs
Publication statusPublished - 27-Feb-2020

Keywords

  • ADAPTED TREATMENT
  • PET
  • ABVD
  • BIOMARKERS
  • TRIAL
  • TARC

Cite this